Sodium aminosalicylate (80% w/w) + Isoniazid (2.33% w/w)

Clinical Pharmacologist's Monograph

⚠️ Prescription Only: This medicine is Schedule H/H1. Do not self-medicate.

1. Clinical Overview

A fixed-dose combination of two first-line anti-tubercular drugs used primarily as a component of multi-drug therapy for the treatment of pulmonary and extra-pulmonary tuberculosis. Sodium aminosalicylate (PAS) is a bacteriostatic agent that inhibits folic acid synthesis, while Isoniazid (INH) is a bactericidal agent that inhibits mycolic acid synthesis in actively dividing tubercle bacilli. This combination is used to prevent the emergence of INH resistance and is a key part of the Category II (re-treatment) regimen under the Revised National Tuberculosis Control Programme (RNTCP), now NTEP (National Tuberculosis Elimination Programme) in India.

OnsetDurationBioavailability
Isoniazid: 1-2 hours for peak plasma concentration. Sodium aminosalicylate: 1-2 hours for peak plasma concentration. Clinical improvement (fever, cough) may be seen within 2-3 weeks.Approximately 24 hours for both components, supporting once-daily dosing.Isoniazid: ~90% (oral). Sodium aminosalicylate: ~70-80% (oral). Bioavailability of PAS is reduced when taken with food.

2. Mechanism of Action

The combination exerts a synergistic anti-mycobacterial effect through two distinct pathways. Isoniazid is a prodrug activated by the bacterial catalase-peroxidase enzyme (KatG). The activated form inhibits the enzyme enoyl-acyl carrier protein reductase (InhA), which is crucial for the synthesis of mycolic acids—long-chain fatty acids essential for the mycobacterial cell wall. This leads to bactericidal activity against actively dividing organisms. Sodium aminosalicylate is a structural analog of para-aminobenzoic acid (PABA). It competitively inhibits the bacterial enzyme dihydropteroate synthase (DHPS), blocking the incorporation of PABA into dihydrofolic acid, a precursor of folic acid. This inhibition depletes folate cofactors required for nucleic acid synthesis, resulting in bacteriostatic activity.

3. Indications & Uses

  • Pulmonary Tuberculosis (as part of multi-drug therapy, typically in re-treatment regimens)
  • Extra-pulmonary Tuberculosis (as part of multi-drug therapy, typically in re-treatment regimens)

4. Dosage & Administration

Adult Dosage: Typical dosage is based on the Isoniazid component: 4-6 mg/kg/day (max 300 mg/day). In this combination, the standard adult dose is often one 4.5g sachet/granules (containing approx. 105 mg Isoniazid and 3.6g Sodium PAS) taken once daily. However, dosing MUST be calculated individually as per NTEP Category II regimen: INH 600 mg + PAS 12g per day in divided doses. The granular form is mixed with water or yogurt.

Administration: Take after food to minimize gastrointestinal irritation from PAS. The granules/powder should be mixed thoroughly in a glass of water, fruit juice, or yogurt immediately before consumption. Do not chew the granules. Administer once daily, preferably at the same time each day. For the full multi-drug regimen, other anti-TB drugs (Rifampicin, Pyrazinamide, Ethambutol) should be taken at their prescribed times, often separately to avoid interactions (especially with Rifampicin).

5. Side Effects

Common side effects may include:

  • Nausea, Vomiting, Diarrhea, Abdominal pain (due to PAS)
  • Anorexia
  • Headache
  • Dizziness
  • Mild skin rash or itching

6. Drug Interactions

DrugEffectSeverity
Aluminum-containing AntacidsDecreased absorption of Isoniazid. Separate administration by at least 2 hours.Moderate
Phenytoin, CarbamazepineINH inhibits metabolism, increasing levels and risk of toxicity (ataxia, nystagmus). Monitor levels and reduce anticonvulsant dose.Major
WarfarinINH may potentiate anticoagulant effect. Monitor INR closely.Major
Benzodiazepines (e.g., Diazepam)INH may inhibit metabolism, increasing sedation.Moderate
TheophyllineINH may increase Theophylline levels. Monitor for toxicity.Moderate
Ketoconazole, ItraconazoleINH may reduce azole levels. Monitor efficacy.Moderate
RifampicinRifampicin induces INH metabolism, potentially lowering INH levels, but this is managed in standard TB regimens. Rifampicin also increases risk of hepatotoxicity.Major
CorticosteroidsMay decrease INH levels by increasing acetylation rate.Moderate
Acetaminophen (Paracetamol)Increased risk of hepatotoxicity, especially in malnourished patients. Avoid excessive doses.Major
Tyramine-rich foods (with INH as MAO inhibitor)Risk of hypertensive crisis (flushing, headache, palpitations).Moderate

7. Patient Counselling

  • DO take the medication exactly as prescribed, at the same time each day, for the full duration (often 6-8 months or more).
  • DO take it after food to reduce stomach upset.
  • DO mix the granules completely in water, juice, or yogurt as instructed. Drink immediately.
  • DO take Pyridoxine (Vitamin B6) supplement if prescribed by your doctor to prevent nerve problems.
  • DO attend all follow-up appointments for sputum tests and monitoring.
  • DON'T stop taking the medicine even if you feel better.
  • DON'T consume ANY alcohol during treatment and for some time after.
  • DON'T take any other medicines (including OTC, Ayurvedic, or home remedies) without consulting your doctor.
  • DON'T share your medicine with anyone else.

8. Toxicology & Storage

Overdose: Isoniazid overdose is a medical emergency. Symptoms appear within 30 min to 3 hours: Severe nausea/vomiting, slurred speech, dizziness, visual hallucinations, seizures (often refractory), metabolic acidosis (high anion gap), hyperglycemia, coma, respiratory distress. PAS overdose: Severe nausea, vomiting, diarrhea, abdominal pain, electrolyte imbalance, metabolic acidosis, crystalluria, possible renal damage.

Storage: Store in a cool, dry place, protected from light and moisture. Keep the container tightly closed. Store at room temperature (15-30°C). Do not freeze. Keep out of reach of children. Do not use after the expiry date printed on the pack.